Mankind Pharma Ltd

For the third consecutive session, Mankind Pharma Ltd has seen its share price decline, culminating in a fresh 52-week low of Rs 1929.55 on 23 Mar 2026. This marks a 7.73% drop over the last three days, reflecting intensified selling pressure amid broader sector weakness.

For the third consecutive session, Mankind Pharma Ltd has seen its share price decline, culminating in a fresh 52-week low of Rs 1929.55 on 23 Mar 2026. This marks a 7.73% drop over the last three days, reflecting sustained selling pressure amid broader sector weakness.

Mankind Pharma Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 March 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Mankind Pharma Ltd’s stock price declined to a fresh 52-week low of Rs.1985.3 today, marking a significant downturn amid ongoing challenges in performance and valuation pressures. The stock has underperformed its sector and benchmark indices, reflecting a cautious market stance towards the mid-cap pharmaceutical company.

Mankind Pharma Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to a more pronounced bearish trend. The stock’s recent price action, combined with mixed signals from MACD, RSI, and moving averages, suggests increasing downside pressure amid a challenging market environment for the pharmaceuticals sector.

Mankind Pharma Ltd experienced a notable decline on 19 Mar 2026, touching an intraday low of Rs 2010.1 as the stock faced significant price pressure amid a broadly bearish market environment and sectoral underperformance.

Mankind Pharma Ltd’s shares declined sharply to a new 52-week low of Rs.2010.1 on 19 Mar 2026, marking a significant drop amid broader sector and market weakness. The stock underperformed its Pharmaceuticals & Biotechnology sector peers and the benchmark indices, reflecting ongoing concerns over valuation and recent financial performance.

Mankind Pharma Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Mankind Pharma Ltd has witnessed a notable surge in open interest in its derivatives segment, signalling heightened market participation and shifting investor positioning. The pharmaceutical mid-cap stock outperformed its sector peers on 10 Mar 2026, buoyed by increased volumes and a positive price trend after a brief correction.

Mankind Pharma Ltd has witnessed a notable surge in open interest in its derivatives segment, signalling increased market participation and shifting investor positioning. The pharmaceutical mid-cap outperformed its sector peers with a 3.15% gain on 10 Mar 2026, supported by rising volumes and a positive reversal after two days of decline.

Mankind Pharma Ltd has witnessed a notable surge in open interest in its derivatives segment, signalling increased market participation and potential directional bets. The stock outperformed its sector peers with a 3.29% gain on 10 Mar 2026, supported by rising volumes and a shift in investor positioning, despite a recent downgrade in its Mojo Grade to Sell.

Mankind Pharma Ltd is rated Sell by MarketsMOJO, with this rating last updated on 19 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 01 March 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Mankind Pharma Ltd (MANKIND) has witnessed a significant surge in open interest (OI) in its derivatives segment, signalling heightened market activity and shifting investor positioning. The stock outperformed its sector and broader indices, supported by robust volume and delivery trends, as investors recalibrate their directional bets amid evolving market dynamics.

Mankind Pharma Ltd has witnessed a significant surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. The pharmaceutical company’s stock has outperformed its sector peers, buoyed by strong volume and rising investor participation, even as its overall rating was downgraded to Sell by MarketsMOJO on 19 Nov 2025.

Mankind Pharma Ltd demonstrated robust intraday performance on 26 Feb 2026, surging to an intraday high of Rs 2,272.55, marking a 5.45% increase from its previous close. This advance outpaced the Pharmaceuticals & Biotechnology sector and the broader market, underscoring the stock’s strong momentum amid a mixed market backdrop.

Mankind Pharma Ltd (MANKIND) has witnessed a significant surge in open interest (OI) in its derivatives segment, signalling heightened market activity and shifting investor positioning. The stock’s recent outperformance against its sector and sustained gains over four consecutive sessions have coincided with a 35.3% jump in open interest, suggesting increased directional bets and renewed investor confidence in the mid-cap pharmaceutical player.

Mankind Pharma Ltd has witnessed a significant surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. The stock has outperformed its sector peers with a 4.29% gain today, extending a four-day winning streak that has delivered an 11.25% return, reflecting growing bullish sentiment despite a recent downgrade in its Mojo Grade to Sell.